



Universiteit
Leiden
The Netherlands

Achieving effective multimodal imaging with rare-earth ion-doped CaF₂ nanoparticles

Yu, Z.F.; He, Y.Y.; Schomann, T.; Wu, K.F.; Hao, Y.; Suidgeest, E.; ... ; Cruz, L.J.

Citation

Yu, Z. F., He, Y. Y., Schomann, T., Wu, K. F., Hao, Y., Suidgeest, E., ... Cruz, L. J. (2022). Achieving effective multimodal imaging with rare-earth ion-doped CaF₂ nanoparticles. *Pharmaceutics*, 14(4). doi:10.3390/pharmaceutics14040840

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3567452>

Note: To cite this publication please use the final published version (if applicable).

Article

Achieving Effective Multimodal Imaging with Rare-Earth Ion-Doped CaF₂ Nanoparticles

Zhenfeng Yu ¹, Yuanyuan He ¹, Timo Schomann ^{1,2}, Kefan Wu ³, Yang Hao ¹, Ernst Suidgeest ⁴, Hong Zhang ³, Christina Eich ^{1,*} and Luis J. Cruz ^{1,*}

¹ Translational Nanobiomaterials and Imaging Group, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; z.yu@lumc.nl (Z.Y.); y.he@lumc.nl (Y.H.); t.schomann@lumc.nl (T.S.); y.hao@lumc.nl (Y.H.)

² Percuros B.V., Zernikedreef 8, 2333 CL Leiden, The Netherlands

³ Van't Hoff Institute for Molecular Sciences, University of Amsterdam, Science Park 904, 1098 XH Amsterdam, The Netherlands; k.wu@uva.nl (K.W.); h.zhang@uva.nl (H.Z.)

⁴ C.J. Gorter Center for High Field MRI, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; e.suidgeest@lumc.nl

* Correspondence: c.eich@lumc.nl (C.E.); l.j.cruz_ricondo@lumc.nl (L.J.C.)

Abstract: Nowadays, cancer poses a significant hazard to humans. Limitations in early diagnosis techniques not only result in a waste of healthcare resources but can even lead to delays in diagnosis and treatment, consequently reducing cure rates. Therefore, it is crucial to develop an imaging probe that can provide diagnostic information precisely and rapidly. Here, we used a simple hydrothermal method to design a multimodal imaging probe based on the excellent properties of rare-earth ions. Calcium fluoride co-doped with ytterbium, gadolinium, and neodymium (CaF₂:Y,Gd,Nd) nanoparticles (NPs) is highly crystalline, homogeneous in morphology, and displays a high biosafety profile. In addition, *in vitro* and *ex vivo* experiments explored the multimodal imaging capability of CaF₂:Y,Gd,Nd and demonstrated the efficient performance of CaF₂:Y,Gd,Nd during NIR-II fluorescence/photoacoustic/magnetic resonance imaging. Collectively, our novel diagnosis nanoparticle will generate new ideas for the development of multifunctional nanoplatforms for disease diagnosis and treatment.

Keywords: rare-earth ions; multimodal imaging; NIR-II fluorescence; photoacoustic; magnetic resonance



Citation: Yu, Z.; He, Y.; Schomann, T.; Wu, K.; Hao, Y.; Suidgeest, E.; Zhang, H.; Eich, C.; Cruz, L.J. Achieving Effective Multimodal Imaging with Rare-Earth Ion-Doped CaF₂ Nanoparticles. *Pharmaceutics* **2022**, *14*, 840. <https://doi.org/10.3390/pharmaceutics14040840>

Academic Editors: Oleh Taratula and Olena Taratula

Received: 7 March 2022

Accepted: 8 April 2022

Published: 11 April 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

To date, countries around the world are facing major challenges posed by cancer. Cancer is a highly recurrent and lethal disease with low cure rates, a continuous increase in patients, inadequate performance of medical equipment, and the serious shortage of medical staff, which have led to the gradual overdraft of the medical system. Consequently, an emerging hot topic is the efficient diagnosis of the condition, as well as quick and rational allocation of medical resources and the reduction of the medical burden. In recent decades, the main diagnosis and treatment methods for the early disease stages included magnetic resonance imaging (MRI) [1,2], X-ray computed tomography (CT) [3,4], positron emission tomography (PET) [5–7], single-photon emission computed tomography (SPECT) [8,9], magnetic particle imaging (MPI) [10,11], and optical fluorescent light imaging (FLI) [12,13]. It is worth noting that photoacoustic imaging (PAI) is expected to become a powerful tool for clinical detection due to its super-spatial resolution, high penetration, and non-invasive imaging technology [14,15]. The application of these detection tools can provide relevant information about patients' diseases and help doctors formulate treatment plans. However, in addition to the advantages of diagnostic tools, each imaging modality has its own disadvantages that cannot be ignored, such as low temporal and/or spatial resolution,

low sensitivity, long response time, etc. [16–18]. This determines that each method can only provide information on a specific aspect, and usually multiple tests are required to combine all the diagnostic information to obtain a relatively comprehensive diagnosis. This is not only time consuming, but also causes a serious waste of medical resources. Thus, the development of an imaging probe that integrates multiple detection functionalities can improve the efficiency of medical diagnosis and alleviate the dilemma faced by the current medical system.

Due to the excellent physical properties of rare-earth elements, i.e., their optical, electrical, and magnetic characteristics, the doping of rare-earth elements with other materials can lead to the formation of new materials with different properties. In this way, rare-earth materials are gradually becoming a focus for research and development of high technology, with application in the treatment and diagnosis of tumors [19]. In addition, rare-earth elements contain unfilled 4f electrons, and the 4f-layer electrons are shielded by the outer layer of 5s², 5p⁶ electrons, which can easily jump between the high energy levels, forming an extremely complex spectrum. This property has laid the foundation for rare earth elements to become superior luminescent materials. Novel trivalent rare-earth ion-doped, inorganic nanomaterials have attracted a great deal of attention in recent years [20–24]. In particular, fluorides with low phonon energy and high chemical stability are considered ideal host materials for lanthanide-doped down-conversion nanomaterials such as SrF₂ [25–27], CaF₂ [28], NaYF₄ [29,30], NaLuF₄ [31,32], and NaGdF₄ [33–35]. Compared to other fluorides, CaF₂ has better biocompatibility and high optical transparency, and can effectively prevent the leakage of rare-earth ions, reducing the possibility of diseases, such as nephrogenic systemic fibrosis [36–39]. It has been established that water has a huge absorption peak during the upconversion process under 980 nm excitation, which can easily cause an overheating effect and damage the organism [40]. However, if the excitation wavelength of the nanomaterial is located in the first near-infrared (NIR) window (650–900 nm), it can effectively reduce light damage, and water reaches its lowest local absorption value around 800 nm. Therefore, we chose Nd³⁺ as the main NIR emitter of the new material, which has a strong absorption cross-section at a wavelength of 808 nm [41–46]. In order to obtain novel materials with high quantum efficiency, one of the issues we have to address is the quenching effect of the luminescence intensity caused by the dose of Nd³⁺ doping [47,48]. A considerable amount of literature has been published regarding the use of Y³⁺ as a modulating ion for the co-doping of Nd³⁺:CaF₂ crystals [49–52]. These studies have confirmed that Y³⁺ as a dopant can effectively destroy the Nd–Nd clusters in the CaF₂ structure, leading to improved material performance. Recently, Li et al. investigated the combined effect on the spectral properties of Nd³⁺, R₁³⁺, R₂³⁺:CaF₂ (R₁, R₂ = Y, La, Gd, Lu) crystals in detail by co-doping several non-optically active regulatory ions into Nd³⁺:CaF₂ crystals, and demonstrated that Nd³⁺, Y³⁺, Gd³⁺:CaF₂ crystals have excellent laser properties [53]. Therefore, we chose a combination of Y³⁺, Gd³⁺, and Nd³⁺ to explore the performance of small-sized CaF₂ nanoparticles (NPs). In addition, the well-known exceptional paramagnetic properties of Gd³⁺ may also help the NPs to achieve MRI with excellent spatial resolution. Therefore, the combination of Y³⁺, Gd³⁺, and Nd³⁺ was chosen to explore the performance of small-sized CaF₂ NPs.

In the present work, we demonstrate a simple synthesis strategy to achieve “three-in-one” imaging of NPs by co-doping rare earth ions (Y³⁺, Gd³⁺, and Nd³⁺) with diverse properties into a CaF₂ matrix using a hydrothermal method (Figure 1). This convenient and efficient synthesis method not only results in NPs with multimodal imaging properties (NIR-II/PA/MRI), but also avoids material loss and performance degradation observed with other multimodal imaging materials due to complex synthesis processes. In addition, the obtained CaF₂:Y,Gd,Nd NPs display uniform morphology, excellent biocompatibility, as well as outstanding imaging properties. The doping of Y³⁺ and Gd³⁺ not only breaks the concentration quenching threshold of Nd³⁺, but also enhances the NIR-II luminescence properties and paramagnetic properties of the NPs, thereby enabling NIR-II and MR imaging of CaF₂:Y,Gd,Nd NPs. Meanwhile, the reaction of the three doping

elements endows $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs with unique photoacoustic properties. In conclusion, our novel, multimodal-imaging material can simultaneously achieve high temporal and spatial resolution.




Figure 1. Predicted three-dimensional (3D) structure of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs.

2. Materials and Methods

2.1. Materials

All chemicals were ready for use without additional purification. Calcium chloride dihydrate ($\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$, 99.5%), yttrium (III) chloride heptahydrate ($\text{YCl}_3 \cdot 6\text{H}_2\text{O}$, 99.99%), neodymium (III) chloride hexahydrate ($\text{NdCl}_3 \cdot 6\text{H}_2\text{O}$, 99.9%), gadolinium (III) chloride hexahydrate ($\text{GdCl}_3 \cdot 6\text{H}_2\text{O}$, 99.9%), ammonium fluoride (NH_4F , $\geq 98.0\%$), potassium citrate tribasic monohydrate ($\text{HOC}(\text{COOK})(\text{CH}_2\text{COOK})_2 \cdot \text{H}_2\text{O}$, $\geq 99.0\%$), and ethylenediaminetetraacetic acid (EDTA) were purchased from Sigma-Aldrich (St. Louis, MO, USA); 4',6'-diamidino-2-phenylindole (DAPI), Dulbecco's modified eagle's medium (DMEM), MHC II-PE, CD86-FITC, and fetal calf serum (FCS, Gibco Laboratories, Brooklyn, NY, USA) were purchased from Thermo Fisher Scientific (Waltham, MA, USA); CellTiter 96 Aqueous MTS reagent powder was purchased from Promega (Madison, WI, USA); lipopolysaccharide (LPS) was purchased from PeproTech (Cranbury, NJ, USA); agarose was purchased from Bioline (London, UK); phalloidin-iFluor 488 Reagent was purchased from Abcam (Cambridge, UK); CD40-APC was purchased from Biolegend (San Diego, CA, USA). All experimental water was deionized (DI) water.

2.2. Synthesis of the $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs

$\text{CaF}_2:\text{Y,Gd,Nd}$ NPs were prepared using a hydrothermal method. In a 100 mL beaker, a total of 3.75 mmol of stoichiometric $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$, $\text{YCl}_3 \cdot 6\text{H}_2\text{O}$, $\text{GdCl}_3 \cdot 6\text{H}_2\text{O}$, and $\text{NdCl}_3 \cdot 6\text{H}_2\text{O}$ ($\text{Ca}^{2+}:\text{Y}^{3+}:\text{Gd}^{3+}:\text{Nd}^{3+} = 0.68:0.15:0.15:0.02$) was dissolved in 7 mL of DI water. A total of 20 mL (6.4882 g) sodium citrate was added dropwise to the above solution and stirred vigorously at 1500 rpm for 20 min (min using a magnetic stirrer (IKA, Staufen, Germany)). Then, NH_4F (0.3241 g) in aqueous solution was added to the previous solution. The obtained clear solution was placed in a Teflon-lined autoclave (Baoshishan, China) and treated at 180 °C for 10 h (h). The autoclave was then cooled to room temperature and

the NPs were collected by centrifugation ($2.4 \times g$, 20 min), washed 3 times with water and ethanol, and then dried using a freeze dryer (Martin Christ, Osterode, Germany).

2.3. Characterization

Powder X-ray diffraction (XRD) patterns were measured using a Panalytical X'pert PRO powder diffractometer (Malvern Panalytical, Malvern, UK) with a $\text{CuK}\alpha$ ($\lambda = 1.5405 \text{ \AA}$) source operating at 40 kV and 40 mA in steps of 6.0° and a 2θ range of $10^\circ \leq 2\theta \leq 70^\circ$. Samples were prepared by pressing the powder onto a slide. Dynamic light scattering (DLS) measurements and zeta potentials of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs dispersed in water were measured using a Malvern ZetaSizer 2000 (Malvern, UK) at room temperature ($\sim 25^\circ \text{C}$). Fourier transform infrared (FT-IR) spectra were recorded using IRSpirit FTIR spectrophotometers (Shimadzu, Kyoto, Japan). Powder samples (without potassium bromide) were averaged over 15 scans at room temperature with a resolution of 4 cm^{-1} . The diameter and morphology of the synthesized $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs were characterized by Tecnai 12 Twin (FEI Company, Hillsboro, OR, USA) transmission electron microscopy (TEM) using a OneView camera Model 1095 (Gatan, Pleasanton, CA, USA) at an accelerating voltage of 120 kV. Samples were prepared by adding 1 mg/mL of $\text{CaF}_2:\text{Y,Gd,Nd}$ aqueous solution to the surface of glow-discharged copper grids. For scanning electron microscopy (SEM) inspection, $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs were mounted on specimen stubs by means of carbon tape. Next, stubs with sample were mounted in an Apreo S LoVac SEM (Thermo Scientific, USA) equipped with an UltraDry energy-dispersive X-ray spectroscopy (EDS) detector (Thermo Scientific, USA). EDS of NPs was performed at $1500\times$ magnification with 30 kV and 51 nA. Emission spectra of NPs at different powers were measured using a Fluorolog[®]-3 with FluorEssence[™] spectrometer (Horiba, Kyoto, Japan), and the samples were placed in a quartz cell. UV and Visible spectra were recorded by an Agilent 8453 UV-visible Spectrometer (absorption, Agilent, Santa Clara, CA, USA) and a SpectraMax[®] iD3 Multi-Mode Microplate Reader (Molecular Devices, San Jose, CA, USA) and aqueous NP solutions (10 mg/mL) were measured in 96-well plates. Vibrating-sample magnetometry (VSM) of the $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs was measured on a Quantum Design Versalab physical property measurement system with the VSM option (Quantum Design, San Diego, CA, USA). Data analysis and processing was performed using Zetasizer Software (Version 7.13), GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA), and Origin 8.5 (OriginLab Corporation, Northampton, MA, USA).

2.4. Stability of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs

A total of 2 mg $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs was dissolved in 10 mL of 50% FCS solution. The samples were mixed thoroughly and placed in a shaker at 37°C . The particle size and zeta potential of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs in the solvent were measured at different time points (0 h, 1 d, 2 d, 3 d, 4 d, 5 d, 6 d, 7 d) using a Malvern ZetaSizer 2000 (Malvern, UK). Data were processed using Zetasizer Software (Version 7.13, Malvern, UK).

2.5. Hemolysis of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs

To investigate the hemolytic potential of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs, an in vitro hemolysis test was carried out. Briefly, a total of 100 μL of fresh blood was collected from the tail vein of BALB/c mice using a vacuum blood collection tube. Then, collected blood was centrifuged at $0.9 \times g$ for 15 min to remove the serum and then washed 4 times with PBS to obtain hemoglobin. The hemoglobin was diluted in 7 portions with $\text{Ca}^{2+}/\text{Mg}^{2+}$ -free PBS and aliquoted in 1.5 mL centrifuge tubes. The supernatant was removed by centrifugation at $0.9 \times g$ for 5 min. Two groups were randomly removed as negative and positive controls. The group resuspended in 500 μL saline was used as the negative control and the group resuspended in 500 μL 1% Triton X-100 (*v/v*) was used as the positive control. Blood cells in the experimental groups were resuspended in isotonic saline containing different concentrations (1, 0.5, 0.25, 0.125, 0.0625 mg/mL) of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs. Samples were gently shaken in a shaker incubator at 37°C for 4 h. Samples were then centrifuged at $0.9 \times g$

and 4 °C for 15 min and the supernatant was transferred to a 96-well plate. The absorbance was measured at 540 nm using an enzyme marker (Molecular Devices SpectraMax, San Jose, CA, USA). The hemolysis values of the samples at 540 nm were calculated as follows:

$$\text{Hemolysis ratio \%} = (\text{OD sample} - \text{OD negative}) / (\text{OD positive} - \text{OD negative}) \times 100$$

2.6. MTS Cytotoxicity Assay of CaF₂:Y,Gd,Nd NPs

In vitro cytotoxicity of CaF₂:Y,Gd,Nd NPs was studied on 4T1 cells. The 4T1 cells (1×10^4) were inoculated in 96-well plates, 100 µL of medium was added to each well, and the cells were allowed to adhere overnight. The medium was then replaced with DMEM containing different concentrations of CaF₂:Y,Gd,Nd NPs (2000, 1000, 500, 250, 125, 62.5, and 31.25 µg/mL). The medium was removed at the indicated intervals (24, 48, and 72 h) and cell viability was assessed by MTS (Promega, Madison, WI, USA) according to the manufacturer's instructions. The absorbance (OD) was measured at 490 nm using an enzyme marker (Molecular Devices, San Jose, CA, USA). Data are expressed as a percentage of the experimental group versus the control group. The experiment was performed in quadruplicate.

2.7. Uptake of CaF₂:Y,Gd,Nd NPs

Cellular uptake of CaF₂:Y,Gd,Nd NPs was examined by a SP8 LIGHTNING Confocal Microscope (Leica Microsystems, Wetzlar, Germany) and flow cytometry (Becton Dickinson, San Jose, CA, USA). Confocal microscopy was used to demonstrate the uptake and distribution of CaF₂:Y,Gd,Nd NPs within 4T1 cells. The 4T1 cells were inoculated in 24-well plates containing coverslips. When the cells reached 50–60% confluence, they were incubated with 1 mL of medium containing 250 µg/mL CaF₂:Y,Gd,Nd NPs for 1, 4, 24, and 48 h. After incubation, the cells were washed 3 times with cold PBS, fixed with 200 µL of 4% paraformaldehyde at room temperature for 20 min, washed twice with cold PBS, treated with 0.1% Triton-X in PBS at room temperature for 15 min, then stained with ghost cyclopeptides for 40 min, and nuclei were stained with DAPI for 5 min. After staining, the cells were viewed and imaged using a SP8 LIGHTNING Confocal Microscope. For flow cytometry, 3×10^4 4T1 cells/well were inoculated in 24-well plates for 24 h. After incubation, the medium was replaced with 1 mL of medium containing 250 µg/mL CaF₂:Y,Gd,Nd NPs and incubated at 37 °C for 1, 4, 24, and 48 h. The cells were then washed 5 times with PBS to remove excess NPs, trypsin digested, resuspended with 100 µL FACS buffer (PBS/0.5% BSA/0.02% sodium azide), and the NP fluorescence was analyzed by LSRFortessa FACS Analyzer (BD Biosciences, Franklin Lakes, NJ, USA) to assess the uptake of NPs by the 4T1 cells.

2.8. In Vitro Dendritic Cell (DC) Activation Study

To assess the immunogenicity of CaF₂:Y,Gd,Nd NPs, D1 DCs were inoculated into 96-well plates and incubated with different concentrations (0–125 µg/mL) of CaF₂:Y,Gd,Nd NPs in an incubator at 37 °C for 24 h. Supernatants were collected for IL-12 assay using an IL-12p40 sandwich ELISA kit (Biolegend, San Diego, CA, USA) and the remaining cells were assessed by flow cytometry to determine the expression of co-stimulatory markers CD86, CD40, and MHC-II. Briefly, D1 DCs were harvested with PBS/EDTA, washed with FACS buffer, and stained with anti-CD40-APC, anti-CD86-FITC, and anti-MHC II-PE. After 30 min of incubation, the cells were washed again with FACS buffer to remove excess antibodies and the stained cells were resuspended in 100 µL FACS buffer. CD86, CD40, and MHC-II expression were measured with an LSR-II cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and analyzed using FlowJo software (version 10).

2.9. In Vitro and Ex Vivo Imaging of CaF₂:Y,Gd,Nd NPs

This study was performed in line with the principles of the Dutch Animal Ethical Commission under license number AVD116008045 and approved by the Animal Experimental Committee from the Leiden University Medical Center (LUMC).

2.9.1. NIR-II Imaging

To evaluate the NIR-II luminescence properties of CaF₂:Y,Gd,Nd NPs, we used the KIS NIR-II optical imaging system (Kaer Labs, Nantes, France). The InGaAs camera was cooled to $-20\text{ }^{\circ}\text{C}$ with a mid-gain setting. The CaF₂:Y,Gd,Nd NPs solution (2 mg/mL) was excited using an 808 nm laser with a laser power of 50 mW/cm^2 to obtain images at different wavelengths. The images were recorded by the KIS NIR-II system.

2.9.2. Photoacoustic Imaging

A Vevo 3100 LAZR-X (FUJIFILM VisualSonics, Toronto, ON, Canada) equipped with an MX550D transducer was used to acquire in vitro and ex vivo PA images of CaF₂:Y,Gd,Nd NPs solutions (10 mg/mL) at 808 nm. In vitro, we measured the intensity of the PAI signal of CaF₂:Y,Gd,Nd NP solution (10 mg/mL), with water as a control, and recorded PA images. Ex vivo, we first took PA images of BALB/c mouse cadavers before injection, and then injected the CaF₂:Y,Gd,Nd NP solution (10 mg/mL) into the abdomen of mice and collected PA images immediately after injection. The measurement procedure was performed with a center transmission of 40 MHz and an axial resolution of 40 μm . Data were analyzed using Vevo LAB 5.5.0 (FUJIFILM VisualSonics, Toronto, ON, Canada).

2.9.3. MRI Studies

To determine that the CaF₂:Y,Gd,Nd NPs were magnetic, MRI measurements were performed on a 7T Bruker BioSpec (Ettlingen, Germany) with a 38 mm transmit/receive birdcage coil. CaF₂:Y,Gd,Nd gels were configured using 5% agarose solution at different concentrations (0 mg/mL, 1 mg/mL, 2.5 mg/mL, 5 mg/mL, 7.5 mg/mL, 10 mg/mL). Then, the samples were placed in a circular test tube for testing, and the T1-weighted images were obtained using the following parameters: the repetition time/echo time (TR/TE) was 500/11 ms, the number of excitations (NEX) was 4, the field of view (FoV) was $40 \times 40\text{ mm}^2$, and the Flipangle (FA) was 180. Next, to test the MRI properties of NPs in a biological environment, we injected 100 μL of CaF₂:Y,Gd,Nd NPs (10 mg/mL) into C57BL/6J mouse cadavers via subcutaneous injection. Images were obtained before and after injection using a small animal coil. The relevant parameters were as following: TR/TE = 10/2.8 ms, FoV = $40 \times 40\text{ mm}^2$, matrix = 256×256 . The attenuation images and results were analyzed with ParaVision 360 (Version 2.0. pl.1, Bruker, Germany) software.

2.10. Statistical Analysis

Statistical analysis was performed using GraphPad Prism software 8 (GraphPad Software, San Diego, CA, USA). Statistical significance of differences is indicated as * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ and **** $p < 0.0001$.

3. Results and Discussion

Firstly, we synthesized small-sized CaF₂:Y,Gd,Nd NPs in a sealed environment under high temperature and pressure using the hydrothermal method developed by Pedroni et al. [54]. The unique physicochemical properties of obtained NPs confer superior optical, magnetic, and photoacoustic characteristics. To better understand the relevant properties of this multifunctional material, we investigated the morphology, biocompatibility, and multimodal imaging aspects of CaF₂:Y,Gd,Nd NPs in detail.

To investigate the morphology of CaF₂:Y,Gd,Nd NPs, we first tested the structure of CaF₂:Y,Gd,Nd NPs using XRD, as shown in Figure 2a. In NP mapping, the diffraction peaks out of (111), (220), (311), and (400) correspond well to the CaF₂ standard card (JCPDS 35-0816) in the cubic phase. Previous studies have shown that the appearance of the (200)

diffraction peak is the primary indication for doping of the CaF_2 crystals with rare-earth ions [52,55]. Therefore, we can determine that the main structure of the NPs is a fluorite-type structure (space group $Fm\bar{3}m$) of CaF_2 [56,57]. On the other hand, the absence of other spurious peaks also indicates that the $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs are in a pure cubic phase. By analyzing the XRD patterns, the crystallite size of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs was calculated as 11.76 ± 1.31 nm using Sherrer formula [58,59]. As this size determination might be susceptible to the influence of the instrument and the sample (microcrystal size, microstrain, etc.), we next determined the diameter of the NPs experimentally.




Figure 2. Morphology of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs. (a) XRD patterns of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs, and CaF_2 ; (b) DLS image of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs (1 mg/mL) before and after freeze drying. Measurements were repeated three times; (c) FTIR image of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs; (d) TEM images of water-soluble $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs; (e) SEM-EDS elemental mapping images of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs. Scale bar = 25 μm .

We found that $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs can be easily dispersed in water to form a stable and transparent solution. To assess the effect of NPs in the colloidal phase and their aggregates, we determined their size and zeta potential. The results showed that after freeze drying, $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs displayed a significant size increase from 24.17 ± 0.3005 nm to 113.4 ± 43.13 nm, with a small reduction in the zeta potential (-12.5 ± 1.15 mV before to -25.7 ± 0.462 mV after freeze drying) (Figure 2b). The increase in NP size might be

caused by aggregation of the NPs due to the freeze-drying process. The high negative zeta potential values, likely caused by the negative groups on the NP surface, indicate a stable system of NPs. Obtaining stable colloidal systems is particularly important in nanomedicine applications [60]. To confirm this speculation, we performed FTIR tests on the sample powder and the appearance of absorption peaks at 1392 cm^{-1} and 1574 cm^{-1} indicated that $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs have carboxyl groups on the surface, thereby confirming our speculation (Figure 2c). To further investigate the morphology, we visualized our $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs by means of TEM. The TEM images showed a more regular paving-stone-like shape with a particle diameter of $12.13 \pm 1.72\text{ nm}$ and an excellent crystallinity which is consistent with the XRD results (Figure 2a,d). Furthermore, EDS was applied for the elemental analysis of freeze-dried $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs, as shown in Supplementary Materials Figure S1. The EDS spectrum showed the peaks of Ca, F, Y, Gd, Nd, and the absence of other impurities. In addition, SEM-EDS elemental mapping revealed that these elements were evenly distributed within the NPs (Figure 2e). These results prove that Ca, F, Y, Gd, Nd elements, and rare earth ions (Y^{3+} , Gd^{3+} , Nd^{3+}) were successfully doped into the CaF_2 matrix. Taken together, our results confirm the successful synthesis of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs.

The key point to determine whether a material can be used as a NIR-II probe is the NIR-II optical property of the material. Based on the results of previous studies [61,62], we tested the emission spectra of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs in the range of 900–1500 nm using an 808 nm laser as the excitation light source, as shown in Figure 3a. The main emission peaks of our NPs were at 1050 nm and 1330 nm, which correspond to the electron transition of Nd^{3+} from the excited state ${}^4\text{F}_{3/2}$ energy level to ${}^4\text{I}_{11/2}$, and ${}^4\text{I}_{13/2}$ levels, respectively [63,64]. Meanwhile, the increase in laser power significantly increased the NIR-II luminescence intensity of Nd^{3+} (Figure 3b). To investigate the NIR-II imaging performance of our NPs, we tested the imaging performance of 2 mg/mL NP solution at different wavelengths. By analyzing the obtained NIR-II image data, we found that $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs exhibit a high contrast at 1050 nm (Figure 3c). This result is consistent with the emission spectra we obtained. Thus, we can determine that our NPs can be used as NIR-II imaging probes.




Figure 3. Optical properties of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs. (a) The emission spectra of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs with different laser powers (excited by an 808 nm laser); (b) the emission intensities of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs (at 1050 nm) with different laser powers under 808 nm laser excitation; (c) in vitro NIR-II emission intensity of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs (2 mg/mL) at different wavelengths (excited by an 808 nm laser, $50\text{ mW}/\text{cm}^2$); inset shows the NIR-II image of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs versus 808 nm excitation.

In addition, to better assess the optical properties in the UV and visible range, we tested the absorption of the NPs using an Agilent 8453 UV-visible Spectrometer and a SpectraMax® iD3 Multi-Mode Microplate Reader. As shown in Figure S2a, absorption at the wavelengths 640 nm and 660 nm was detected. After excitation with 620 nm, the NPs showed significant emission at the range of 680–850 nm, thus allowing imaging of the NPs by means of confocal microscopy (Figure S2b).

The stability and hemolysis properties of NPs are important factors in determining whether NPs can be used for bio-diagnostics. When NPs enter the blood stream, the interaction of the NPs with blood components may affect the aggregation of NPs at the target site. Therefore, the stability of an ideal NP-based imaging probe is not disturbed in a complex biological environment and the imaging probe can be delivered to the target site with maximal efficacy, rather than being toxic to blood components. To investigate the stability of our NPs under physiological conditions, the NPs were resuspended in medium containing 50% FCS, and their size and charge was characterized by DLS over a period of 7 days. We found that the size of all CaF₂:Y,Gd,Nd NPs increased compared to NPs dissolved in water (Figures 2b and 4a), and the zeta potential of CaF₂:Y,Gd,Nd NPs shifted to a higher positive charge with a potential close to 0 mV (Figure 4b). This phenomenon may result from the adsorption of cations or serum proteins in solution by the negative charge on the surface of the NPs [65,66]. To assess the toxicity of NPs on blood cells, we performed hemolysis experiments. After incubation of erythrocytes with NPs at different concentrations for 4 h, as shown in Figure 4c,d, the percentage of hemolysis was close to 0 for all samples compared to the non-hemolyzed positive control group. This result effectively proves that CaF₂:Y,Gd,Nd NPs do not cause toxicity to erythrocytes. In conclusion, our CaF₂:Y,Gd,Nd NPs can be used for bio-diagnostics.




Figure 4. Stability and hemolysis of CaF₂:Y,Gd,Nd NPs. (a) Size and (b) zeta potential of CaF₂:Y,Gd,Nd NPs in 50% FCS; (c) hemolysis of CaF₂:Y,Gd,Nd NPs after incubation with red blood cells at various concentrations (0–1 mg/mL) for 4 h; (d) hemolysis image after centrifugation. All experiments were conducted in three independent experiments and data are expressed as mean ± SD. Statistical significance was calculated by comparing the experimental group with the control group using one-way ANOVA (**** $p < 0.0001$).

Assessing the toxicity of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs is an important indicator to ensure their biosafety. Here, 4T1 cells were used as an assessment model and 4T1 cells were incubated with different concentrations of NPs for 24, 48, and 72 h and then analyzed by MTS assay. In Figure 5, in comparison with the control group, we found that $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs barely affected the metabolic activity of 4T1 cells 24 h after incubation, while the metabolic activity was decreased to 75% at concentrations of 500 $\mu\text{g}/\text{mL}$ and 1000 $\mu\text{g}/\text{mL}$ after 48 h. After 72 h of incubation, the metabolic activity of 4T1 cells decreased only at a NP concentration of 1000 $\mu\text{g}/\text{mL}$, while lower concentrations did not induce any cytotoxic effects. While our results show that $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs did not exhibit cytotoxicity, further in vivo toxicity studies are needed to determine whether $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs are suitable for applications in living organisms.




Figure 5. Viability of 4T1 cells incubated with $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs at increasing concentrations (0–2 mg/mL) after (a) 24; (b) 48; and (c) 72 h assessed by MTS assay. All data are expressed as mean \pm SD from three independent experiments. Statistical significance was calculated using the *t*-test, by comparing experimental groups to the control group (* $p < 0.05$, ** $p < 0.01$).

$\text{CaF}_2:\text{Y,Gd,Nd}$ NPs' optical characteristics partially overlap with the excitation and emission spectra of dyes used in flow cytometry and confocal microscopy, such as Alexa Fluor 647. Thus, we explored whether $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs could be used directly to measure the cellular uptake of NPs by flow cytometry and confocal microscopy (Figure 2d,e). Rare-earth NPs represent a promising tool for the early detection and treatment of cancer. For breast cancer in particular, the development of new imaging probes is desperately needed, because mammography, the standard diagnosis method, often leads to false-negative results and therefore to therapeutic delays [67]. In order to ensure that $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs could be taken up efficiently by breast cancer cells to achieve high-contrast bioimaging, we first analyzed the uptake of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs by 4T1 cells at different time points by using flow cytometry. As shown in Figure 6a, compared to the control group, the uptake efficiency of NPs was low during a short period of time, but gradually increased with

time. To verify this conclusion, we used confocal microscopy to visualize the uptake of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs. As shown in Figure 6b, the signal of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs (magenta) was barely observed after 1 h of incubation, while a larger amount of signal could be observed as the incubation time increased. This result was consistent with the results obtained by flow cytometry. Therefore, we can conclude that $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs were effectively taken up by 4T1 cells. Moreover, $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs were intrinsically monitorable by flow cytometry and confocal imaging.




Figure 6. Uptake of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs by 4T1 cells. (a) Representative flow cytometric plots and (b) flow cytometric analysis of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs uptake by 4T1 cells; (c) confocal microscope images of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs uptake after 1, 4, 24, and 48 h. Cell nuclei are stained blue (DAPI), actin cytoskeleton is green (Phalloidin), and $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs are displayed in magenta. Scale bar = 50 μm .

Understanding whether NPs will interact with the immune system is as important as analyzing their hemolytic properties. It is well known that immune cells in blood and tissues have a tendency to phagocytose and eliminate certain NPs, which may lead to artificial activation of the immune system and cause undesirable systemic side effects. Thus, a good imaging probe must be “invisible” to immune cells. This attribute allows nanoparticles to remain in circulation for a prolonged time without being cleared by immune cells [68]. To assess whether $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs induce an immune response in the

body, we incubated D1DCs with NPs at different concentrations (0–125 $\mu\text{g}/\text{mL}$). After 24 h, we measured the expression of co-stimulatory markers CD86, CD40, and MHC-II and the production of the pro-inflammatory cytokine IL-12. As shown in Figure 7b, the presence of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs did not induce the expression of CD86, CD40, and MHC-II compared to the positive control treated with TLR-3 ligand poly (I:C) (Figure 7a). Additionally, the supernatant was collected and IL-12 production was assessed using ELISA. We found that NPs did not induce the production of the pro-inflammatory cytokine IL-12 at any concentration (Figure 7c). Overall, these studies indicate that $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs are inert and non-immunogenic and can be used as potential bioimaging probes.




Figure 7. Immunogenicity of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs measured by flow cytometry and IL-12 ELISA. D1 DCs were incubated with different concentrations of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs for 24 h. (a) Expression of CD40, CD86, and MHC-II in poly I:C group (compared to untreated group); (b) expression of CD40, CD86, and MHC-II in $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs group (compared to untreated group); (c) production of IL-12 (ng/mL) was measured using ELISA for poly I:C group and $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs group. Data are expressed as mean \pm SD for three independent experiments.

The presence of the element Gd^{3+} , which possesses a high atomic number, makes it possible for $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs to be used as a contrast agent in MRI [69–71]. To verify the magnetic properties of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs, VSM measurement is required. As we expected, the NPs exhibited typical paramagnetic behavior at room temperature (300 K) in an applied magnetic field of 1.5 T, indicating that the NPs are paramagnetically responsive to external magnetic fields (Figure 8a). This is consistent with previous studies, offering the possibility of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs as MR probes [72,73]. Then, T1-weighted MRI scans were performed on agarose-gel-embedded samples with different concentrations of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs. As the results in Figure 8b,c show, the signal intensity of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs was positively correlated with the recovery time, and the analysis shows that the T1 value of the samples was higher and the signal intensity of the T1-weighted MRI increased with increasing sample concentration. Subsequently, to test the MRI performance of $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs within a complex environment, $\text{CaF}_2:\text{Y,Gd,Nd}$ NPs (10 mg/mL) were injected subcutaneously into a mouse cadaver and a significant signal could be observed at the site of injection by means of MRI (Figure 8d). Therefore, when used as a contrast agent, paramagnetic $\text{CaF}_2:\text{Y,Gd,Nd}$

NPs can effectively improve MRI efficiency and sensitivity. Currently, lanthanide-doped NPs are gradually applied to high-contrast PA imaging [74,75]. To investigate this property, we first performed in vitro PA measurements on CaF₂:Y,Gd,Nd NPs and found that the presence of CaF₂:Y,Gd,Nd NPs significantly enhanced the PA signal compared to water, with PA amplitudes up to 0.464 AU (arbitrary unit; Figure 8e). On this basis, we further evaluated the potential of CaF₂:Y,Gd,Nd NPs as a PAI agent by intraperitoneal injection of CaF₂:Y,Gd,Nd NPs in mouse cadavers. When compared to the PAI signal before injection of the NPs, a distinct PAI signal could be observed at 808 nm at the injection site after injection. The PAI signal of the NPs could be well distinguished from the surrounding tissue (Figure 8f). The success of our ex vivo PAI experiments illustrates that CaF₂:Y,Gd,Nd NPs can be used as excellent PAI contrast agents for tissue imaging and diagnosis. In addition to their application as NIR/PAI contrast agent, our CaF₂:Y,Gd,Nd NPs can also be used as a MRI contrast agent.




Figure 8. Cont.




Figure 8. MRI and PAI performance of CaF₂:Y,Gd,Nd NPs. (a) The VSM measurement of CaF₂:Y,Gd,Nd NPs; (b) MRI signal intensity of different concentrations of CaF₂:Y,Gd,Nd NPs with increasing recovery time; (c) in vitro T1 relaxation rates of different CaF₂:Y,Gd,Nd NP concentrations; inset shows T1-weighted MRI images of CaF₂:Y,Gd,Nd NPs at different concentrations in 0.5% agarose gel; (d) ex vivo MRI images before and after subcutaneous injection of CaF₂:Y,Gd,Nd NPs (10 mg/mL) into a mouse cadaver; (e) in vitro PA images (2D and 3D) of CaF₂:Y,Gd,Nd NPs (10 mg/mL), water is the control; (f) ex vivo PA images (3D) before and after injection of CaF₂:Y,Gd,Nd NPs (10 mg/mL) into a mouse. Unspecific signal is caused by endogenous tissue chromophores.

4. Conclusions

Small-sized CaF₂:Y,Gd,Nd NPs synthesized by a facile hydrothermal method can be used as multimodal NIR-II fluorescence/photoacoustic/magnetic resonance imaging probes. The excellent morphology and NIR-II optical properties provide the basis for NIR-II diagnostic applications of our CaF₂:Y,Gd,Nd NPs. Biotoxicity and stability analyses have shown that our NPs are biocompatible as well as safe in biological settings. In addition, the fact that immune cells were not activated in response to CaF₂:Y,Gd,Nd NPs provides favorable leverage for their application in vivo. The doping of Gd³⁺ significantly increased the MRI contrast of CaF₂:Y,Gd,Nd NPs, thereby enabling accurate MRI diagnostic properties. In addition, the apparent PAI signal offers a wide range of applications for CaF₂:Y,Gd,Nd NPs in PAI-based diagnostics. Thus, our work not only demonstrates a multifunctional NP with excellent three-mode imaging capability, but also provides a potential solution to the medical system dilemma. A hot trend in current research is to equip rare-earth NPs with therapeutic functions through surface modifications (antibodies, chemotherapeutic agents, or photosensitizers, etc.), while achieving multimodal imaging of tumor sites [76–79]. In particular, surface modification with tumor-targeting ligands can enhance the potential of rare-earth NPs for cancer diagnosis and treatment [19]. We strongly believe that this study provides an important insight into the design of novel multifunctional nanomaterials as potential therapeutic agents for the treatment and diagnosis of diseases in the future, and helps to drive the clinical translation of novel therapeutic agents.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/pharmaceutics14040840/s1>, Figure S1: EDS spectrum of CaF₂:Y,Gd,Nd NPs; Figure S2: Absorption and emission spectra of CaF₂:Y,Gd,Nd NPs in the visible region.

Author Contributions: Original data collection and analysis, or interpretation—Z.Y., Y.H. (Yuanyuan He), T.S., K.W., Y.H. (Yang Hao) and E.S.; writing—original draft—Z.Y.; visualization—Z.Y.; writing—review and editing—Z.Y., T.S., H.Z., C.E. and L.J.C.; supervision—C.E. and L.J.C. All authors have read and agreed to the published version of the manuscript.

Funding: Luis J. Cruz was supported by project grants from the European Commission: Marie Skłodowska Curie grant agreement CANCER (777682), PRISAR2 (872860), ACORN (807281), SIMICA (852985), BIOSAFETY (952520), PAVE (861190), CAST (857894), NOVA-MRI (859908), PIANO (956477). Christina Eich was supported by the H2020-WIDESPREAD-2018-03 (852985—SIMICA) project grant from the European Commission, and the Dutch PPS allowance made available by Health~Holland, Top Sector Life Sciences and Health for the project NANOCAS2. Timo Schomann received financial support from project grants from the European Commission H2020-MSCA-RISE CANCER (777682) and H2020-WIDESPREAD-05-2017-Twinning SIMICA (852985). Yuanyuan He received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska Curie grant agreement CANCER (777682) and PRISAR2 (872860). Zhenfeng Yu and Yang Hao received financial support from the China Scholarship Council.

Institutional Review Board Statement: This study was performed in line with the principles of the Dutch Animal Ethical Commission with the license of project AVD116008045 and approved by the Animal Experimental Committee from the Leiden University Medical Center (LUMC).

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We would like to thank Roman Koning and Aat Mulder from the Koster lab at LUMC with the excellent support with electron microscopy. We also would like to thank Kaer Labs for the help with the excellent NIR-II imaging. The authors thank Marcel Hesselberth from the Leiden Institute of Physics (The Netherlands) for his help with SEM and EDX, Anton Lefering from Delft University of Technology (The Netherlands) with VSM measurement and the Pre-clinical Imaging Facility with the MRI measurements.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ahmad, M.Y.; Yue, H.; Tegafaw, T.; Liu, S.; Ho, S.L.; Lee, G.H.; Nam, S.-W.; Chang, Y. Functionalized Lanthanide Oxide Nanoparticles for Tumor Targeting, Medical Imaging, and Therapy. *Pharmaceutics* **2021**, *13*, 1890. [[CrossRef](#)] [[PubMed](#)]
2. Liu, K.; Yan, X.; Xu, Y.-J.; Dong, L.; Hao, L.-N.; Song, Y.-H.; Li, F.; Su, Y.; Wu, Y.-D.; Qian, H.-S. Sequential growth of CaF₂:Yb, Er@CaF₂:Gd nanoparticles for efficient magnetic resonance angiography and tumor diagnosis. *Biomater. Sci.* **2017**, *5*, 2403–2415. [[CrossRef](#)] [[PubMed](#)]
3. Middei, S. Neuroimaging Applications for Diagnosis and Therapy of Pathologies in the Central and Peripheral Nervous System. *Brain Sci.* **2022**, *12*, 207. [[CrossRef](#)] [[PubMed](#)]
4. Zheng, N.; Zhang, S.; Wang, L.; Qi, Z.; Peng, Q.; Jian, L.; Bai, Y.; Feng, Y.; Shen, J.; Wang, R. Boosting image-guiding radiation therapy through W₁₈O₄₉ nanospheres and the second near-infrared light irradiation. *Nano Res.* **2022**, *15*, 2315–2323. [[CrossRef](#)]
5. Williamson, C.W.; Sirák, I.; Xu, R.; Portelance, L.; Wei, L.; Tarnawski, R.; Mahantshetty, U.; Heide, E.S.; Yashar, C.M.; McHale, M.T. Positron emission tomography-guided bone marrow-sparing radiation therapy for locoregionally advanced cervix cancer: Final results from the INTERTECC Phase II/III trial. *Int. J. Radiat. Oncol. Biol. Phys.* **2022**, *112*, 169–178. [[CrossRef](#)]
6. Abdalla, A.S.; Sheybani, N.D.; Khan, S.A. Clinical Role of Positron Emission Tomography/Computed Tomography Imaging in Head and Neck Squamous Cell Carcinoma. *PET Clin.* **2022**, *17*, 213–222. [[CrossRef](#)]
7. Weber, W.A. Positron emission tomography as an imaging biomarker. *J. Clin. Oncol.* **2006**, *24*, 3282–3292. [[CrossRef](#)]
8. Carey, P.D.; Warwick, J.; Niehaus, D.J.; Van der Linden, G.; Van Heerden, B.B.; Harvey, B.H.; Seedat, S.; Stein, D.J. Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. *BMC Psychiatry* **2004**, *4*, 30. [[CrossRef](#)]
9. Das, J.P.; Yeh, R.; Schöder, H. Clinical utility of perfusion (Q)-single-photon emission computed tomography (SPECT)/CT for diagnosing pulmonary embolus (PE) in COVID-19 patients with a moderate to high pre-test probability of PE. *Eur. J. Nucl. Med. Mol. Imaging* **2021**, *48*, 794–799. [[CrossRef](#)]
10. Saritas, E.U.; Goodwill, P.W.; Croft, L.R.; Konkole, J.J.; Lu, K.; Zheng, B.; Conolly, S.M. Magnetic particle imaging (MPI) for NMR and MRI researchers. *J. Magn. Reson.* **2013**, *229*, 116–126. [[CrossRef](#)]
11. Bulte, J.W. Superparamagnetic iron oxides as MPI tracers: A primer and review of early applications. *Adv. Drug Deliv. Rev.* **2019**, *138*, 293–301. [[CrossRef](#)] [[PubMed](#)]

12. Lauwerends, L.J.; Galema, H.A.; Hardillo, J.A.; Sewnaik, A.; Monserez, D.; van Driel, P.B.; Verhoef, C.; Baatenburg de Jong, R.J.; Hilling, D.E.; Keereweer, S. Current Intraoperative Imaging Techniques to Improve Surgical Resection of Laryngeal Cancer: A Systematic Review. *Cancers* **2021**, *13*, 1895. [[CrossRef](#)] [[PubMed](#)]
13. Thompson, J.M.; Miller, L.S. Preclinical optical imaging to study pathogenesis, novel therapeutics and diagnostics against orthopaedic infection. *J. Orthop. Res.* **2019**, *37*, 2269–2277. [[CrossRef](#)] [[PubMed](#)]
14. Kyrkou, S.G.; Vrettos, E.I.; Gorpas, D.; Crook, T.; Syed, N.; Tzakos, A.G. Design Principles Governing the Development of Theranostic Anticancer Agents and Their Nanoformulations with Photoacoustic Properties. *Pharmaceutics* **2022**, *14*, 362. [[CrossRef](#)]
15. Li, P.; He, X.; Li, Y.; Lam, J.W.Y.; Kwok, R.T.K.; Wang, C.C.; Xia, L.G.; Tang, B.Z. Recent advances in aggregation-induced emission luminogens in photoacoustic imaging. *Eur. J. Nucl. Med. Mol. Imaging* **2022**, 1–24. [[CrossRef](#)]
16. Seo, Y.; Mari, C.; Hasegawa, B.H. Technological development and advances in single-photon emission computed tomography/computed tomography. *Semin. Nucl. Med.* **2008**, *38*, 177–198. [[CrossRef](#)]
17. Wickline, S.A.; Lanza, G.M. Nanotechnology for molecular imaging and targeted therapy. *Circulation* **2003**, *107*, 1092–1095. [[CrossRef](#)]
18. Kasban, H.; El-Bendary, M.; Salama, D. A comparative study of medical imaging techniques. *Int. J. Inf. Sci. Intell. Syst.* **2015**, *4*, 37–58.
19. Fan, Q.; Cui, X.; Guo, H.; Xu, Y.; Zhang, G.; Peng, B. Application of rare earth-doped nanoparticles in biological imaging and tumor treatment. *J. Biomater. Appl.* **2020**, *35*, 237–263. [[CrossRef](#)]
20. Ding, M.; Chen, D.; Wan, Z.; Zhou, Y.; Zhong, J.; Xi, J.; Ji, Z. Achieving efficient Tb³⁺ dual-mode luminescence via Gd-sublattice-mediated energy migration in a NaGdF₄ core-shell nanoarchitecture. *J. Mater. Chem. C* **2015**, *3*, 5372–5376. [[CrossRef](#)]
21. Dai, Y.; Ma, P.a.; Cheng, Z.; Kang, X.; Zhang, X.; Hou, Z.; Li, C.; Yang, D.; Zhai, X.; Lin, J. Up-conversion cell imaging and pH-induced thermally controlled drug release from NaYF₄:Yb³⁺/Er³⁺@ hydrogel core-shell hybrid microspheres. *ACS Nano* **2012**, *6*, 3327–3338. [[CrossRef](#)] [[PubMed](#)]
22. Li, C.; Lin, J. Rare earth fluoride nano-/microcrystals: Synthesis, surface modification and application. *J. Mater. Chem.* **2010**, *20*, 6831–6847. [[CrossRef](#)]
23. Kumar, R.; Nyk, M.; Ohulchanskyy, T.Y.; Flask, C.A.; Prasad, P.N. Combined optical and MR bioimaging using rare earth ion doped NaYF₄ nanocrystals. *Adv. Funct. Mater.* **2009**, *19*, 853–859. [[CrossRef](#)]
24. Gai, S.; Yang, P.; Li, C.; Wang, W.; Dai, Y.; Niu, N.; Lin, J. Synthesis of magnetic, up-conversion luminescent, and mesoporous core-shell-structured nanocomposites as drug carriers. *Adv. Funct. Mater.* **2010**, *20*, 1166–1172. [[CrossRef](#)]
25. Zhang, C.; Hou, Z.; Chai, R.; Cheng, Z.; Xu, Z.; Li, C.; Huang, L.; Lin, J. Mesoporous SrF₂ and SrF₂:Ln³⁺ (Ln = Ce, Tb, Yb, Er) hierarchical microspheres: Hydrothermal synthesis, growing mechanism, and luminescent properties. *J. Phys. Chem. C* **2010**, *114*, 6928–6936. [[CrossRef](#)]
26. Peng, J.; Hou, S.; Liu, X.; Feng, J.; Yu, X.; Xing, Y.; Su, Z. Hydrothermal synthesis and luminescence properties of hierarchical SrF₂ and SrF₂:Ln³⁺ (Ln = Er, Nd, Yb, Eu, Tb) micro/nanocomposite architectures. *Mater. Res. Bull.* **2012**, *47*, 328–332. [[CrossRef](#)]
27. Chen, D.; Yu, Y.; Huang, F.; Lin, H.; Huang, P.; Yang, A.; Wang, Z.; Wang, Y. Lanthanide dopant-induced formation of uniform sub-10 nm active-core/active-shell nanocrystals with near-infrared to near-infrared dual-modal luminescence. *J. Mater. Chem.* **2012**, *22*, 2632–2640. [[CrossRef](#)]
28. Zheng, W.; Zhou, S.; Chen, Z.; Hu, P.; Liu, Y.; Tu, D.; Zhu, H.; Li, R.; Huang, M.; Chen, X. Sub-10 nm Lanthanide-Doped CaF₂ Nanoprobes for Time-Resolved Luminescent Biodetection. *Angew. Chem.* **2013**, *125*, 6803–6808. [[CrossRef](#)]
29. Li, C.; Quan, Z.; Yang, J.; Yang, P.; Lin, J. Highly uniform and monodisperse β-NaYF₄:Ln³⁺ (Ln = Eu, Tb, Yb/Er, and Yb/Tm) hexagonal micropillar crystals: Hydrothermal synthesis and luminescent properties. *Inorg. Chem.* **2007**, *46*, 6329–6337. [[CrossRef](#)]
30. Dong, B.; Song, H.; Yu, H.; Zhang, H.; Qin, R.; Bai, X.; Pan, G.; Lu, S.; Wang, F.; Fan, L. Upconversion properties of Ln³⁺ doped NaYF₄/polymer composite fibers prepared by electrospinning. *J. Phys. Chem. C* **2008**, *112*, 1435–1440. [[CrossRef](#)]
31. Jia, G.; You, H.; Song, Y.; Jia, J.; Zheng, Y.; Zhang, L.; Liu, K.; Zhang, H. Facile chemical conversion synthesis and luminescence properties of uniform Ln³⁺ (Ln = Eu, Tb)-doped NaLuF₄ nanowires and LuBO₃ microdisks. *Inorg. Chem.* **2009**, *48*, 10193–10201. [[CrossRef](#)] [[PubMed](#)]
32. He, F.; Niu, N.; Zhang, Z.; Zhang, X.; Wang, D.; Bai, L.; Gai, S.; Li, X.; Yang, P. Morphology-controllable synthesis and enhanced luminescence properties of β-NaLuF₄:Ln (Ln = Eu, Tb and Ce/Tb) microcrystals by solvothermal process. *RSC Adv.* **2012**, *2*, 7569–7577. [[CrossRef](#)]
33. Dong, C.; Pichaandi, J.; Regier, T.; van Veggel, F.C. Nonstatistical dopant distribution of Ln³⁺-doped NaGdF₄ nanoparticles. *J. Phys. Chem. C* **2011**, *115*, 15950–15958. [[CrossRef](#)]
34. Song, Y.; Shao, B.; Feng, Y.; Lü, W.; Liu, G.; You, H. A novel strategy to enhance the luminescence performance of NaGdF₄:Ln³⁺ nanocrystals. *Dalton Trans.* **2016**, *45*, 9468–9476. [[CrossRef](#)]
35. Wang, F.; Fan, X.; Wang, M.; Zhang, Y. Multicolour PEI/NaGdF₄:Ce³⁺, Ln³⁺ nanocrystals by single-wavelength excitation. *Nanotechnology* **2006**, *18*, 025701. [[CrossRef](#)]
36. Grobner, T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? *Nephrol. Dial. Transplant.* **2006**, *21*, 1104–1108. [[CrossRef](#)]
37. Amuluru, L.; High, W.; Hiatt, K.M.; Ranville, J.; Shah, S.V.; Malik, B.; Swaminathan, S. Metal deposition in calcific uremic arteriolopathy. *J. Am. Acad. Dermatol.* **2009**, *61*, 73–79. [[CrossRef](#)]

38. Chen, G.; Shen, J.; Ohulchanskyy, T.Y.; Patel, N.J.; Kutikov, A.; Li, Z.; Song, J.; Pandey, R.K.; Ågren, H.; Prasad, P.N. (α -NaYbF₄:Tm³⁺)/CaF₂ core/shell nanoparticles with efficient near-infrared to near-infrared upconversion for high-contrast deep tissue bioimaging. *ACS Nano* **2012**, *6*, 8280–8287. [[CrossRef](#)]
39. Wang, Y.F.; Sun, L.D.; Xiao, J.W.; Feng, W.; Zhou, J.C.; Shen, J.; Yan, C.H. Rare-Earth Nanoparticles with Enhanced Upconversion Emission and Suppressed Rare-Earth-Ion Leakage. *Chem. Eur. J.* **2012**, *18*, 5558–5564. [[CrossRef](#)]
40. Zhan, Q.; Qian, J.; Liang, H.; Somesfalean, G.; Wang, D.; He, S.; Zhang, Z.; Andersson-Engels, S. Using 915 nm laser excited Tm³⁺/Er³⁺/Ho³⁺-doped NaYbF₄ upconversion nanoparticles for in vitro and deeper in vivo bioimaging without overheating irradiation. *ACS Nano* **2011**, *5*, 3744–3757. [[CrossRef](#)]
41. Becker, A.; Hassenius, C.; Licha, K.; Ebert, B.; Sukowski, U.; Semmler, W.; Wiedenmann, B.; Grötzinger, C. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. *Nat. Biotechnol.* **2001**, *19*, 327–331. [[CrossRef](#)] [[PubMed](#)]
42. Weissleder, R. A clearer vision for in vivo imaging. *Nat. Biotechnol.* **2001**, *19*, 316–317. [[CrossRef](#)] [[PubMed](#)]
43. Smith, A.M.; Mancini, M.C.; Nie, S. Second window for in vivo imaging. *Nat. Nanotechnol.* **2009**, *4*, 710–711. [[CrossRef](#)]
44. Pokhrel, M.; Mimun, L.; Yust, B.; Kumar, G.; Dhanale, A.; Tang, L.; Sardar, D. Stokes emission in GdF₃:Nd³⁺ nanoparticles for bioimaging probes. *Nanoscale* **2014**, *6*, 1667–1674. [[CrossRef](#)] [[PubMed](#)]
45. Li, X.; Wang, R.; Zhang, F.; Zhou, L.; Shen, D.; Yao, C.; Zhao, D. Nd³⁺ sensitized up/down converting dual-mode nanomaterials for efficient in-vitro and in-vivo bioimaging excited at 800 nm. *Sci. Rep.* **2013**, *3*, 3536. [[CrossRef](#)]
46. Wang, Y.-F.; Liu, G.-Y.; Sun, L.-D.; Xiao, J.-W.; Zhou, J.-C.; Yan, C.-H. Nd³⁺-sensitized upconversion nanophosphors: Efficient in vivo bioimaging probes with minimized heating effect. *ACS Nano* **2013**, *7*, 7200–7206. [[CrossRef](#)]
47. Bausa, L.; Legros, R.; Muñoz-Yagüe, A. Effect of Nd³⁺ concentration on the emission spectra of CaF₂:Nd layers grown by molecular-beam epitaxy. *J. Appl. Phys.* **1991**, *70*, 4485–4489. [[CrossRef](#)]
48. Stroud, J.S. Concentration Quenching of Nd³⁺ Fluorescence. *Appl. Opt.* **1968**, *7*, 751–757. [[CrossRef](#)]
49. Su, L.; Wang, Q.; Li, H.; Brasse, G.; Camy, P.; Doualan, J.; Braud, A.; Moncorgé, R.; Zhan, Y.; Zheng, L. Spectroscopic properties and CW laser operation of Nd, Y-codoped CaF₂ single crystals. *Laser Phys. Lett.* **2013**, *10*, 035804. [[CrossRef](#)]
50. Quintanilla, M.; Zhang, Y.; Liz-Marzan, L.M. Subtissue plasmonic heating monitored with CaF₂:Nd³⁺, Y³⁺ nanothermometers in the second biological window. *Chem. Mater.* **2018**, *30*, 2819–2828. [[CrossRef](#)]
51. Qin, Z.; Xie, G.; Ma, J.; Ge, W.; Yuan, P.; Qian, L.; Su, L.; Jiang, D.; Ma, F.; Zhang, Q. Generation of 103 fs mode-locked pulses by a gain linewidth-variable Nd, Y:CaF₂ disordered crystal. *Opt. Lett.* **2014**, *39*, 1737–1739. [[CrossRef](#)] [[PubMed](#)]
52. Yu, Z.-f.; Shi, J.-p.; Li, J.-l.; Li, P.-h.; Zhang, H.-w. Luminescence enhancement of CaF₂:Nd³⁺ nanoparticles in the second near-infrared window for in vivo imaging through Y³⁺ doping. *J. Mater. Chem. B* **2018**, *6*, 1238–1243. [[CrossRef](#)] [[PubMed](#)]
53. Li, X.; Hao, Q.; Jiang, D.; Wu, Q.; Zhang, Z.; Zhang, Z.; Liu, J.; Su, L. Smooth and flat photoluminescence spectra of Nd³⁺ active ions in tri-doped CaF₂ single crystals. *Opt. Mater. Express* **2020**, *10*, 704–714. [[CrossRef](#)]
54. Pedroni, M.; Piccinelli, F.; Passuello, T.; Polizzi, S.; Ueda, J.; Haro-González, P.; Martínez Maestro, L.; Jaque, D.; García-Sole, J.; Bettinelli, M. Water (H₂O and D₂O) dispersible NIR-to-NIR upconverting Yb³⁺/Tm³⁺ doped MF₂ (M = Ca, Sr) colloids: Influence of the host crystal. *Cryst. Growth Des.* **2013**, *13*, 4906–4913. [[CrossRef](#)]
55. Bensalah, A.; Mortier, M.; Patriarche, G.; Gredin, P.; Vivien, D. Synthesis and optical characterizations of undoped and rare-earth-doped CaF₂ nanoparticles. *J. Solid State Chem.* **2006**, *179*, 2636–2644. [[CrossRef](#)]
56. Pandurangappa, C.; Lakshminarasappa, B.; Nagabhushana, B. Synthesis and characterization of CaF₂ nanocrystals. *J. Alloys Compd.* **2010**, *489*, 592–595. [[CrossRef](#)]
57. Gerward, L.; Olsen, J.S.; Steenstrup, S.; Malinowski, M.; Åsbrink, S.; Waskowska, A. X-ray diffraction investigations of CaF₂ at high pressure. *J. Appl. Crystallogr.* **1992**, *25*, 578–581. [[CrossRef](#)]
58. Monshi, A.; Foroughi, M.R.; Monshi, M.R. Modified Scherrer equation to estimate more accurately nano-crystallite size using XRD. *World J. Nano Sci. Eng.* **2012**, *2*, 160. [[CrossRef](#)]
59. Uvarov, V.; Popov, I. Metrological characterization of X-ray diffraction methods at different acquisition geometries for determination of crystallite size in nano-scale materials. *Mater. Charact.* **2013**, *85*, 111–123. [[CrossRef](#)]
60. Darwish, M.S.; Stibor, I. Pentenoic acid-stabilized magnetic nanoparticles for nanomedicine applications. *J. Dispers. Sci. Technol.* **2016**, *37*, 1793–1798. [[CrossRef](#)]
61. Wang, Z.; Zhang, P.; Yuan, Q.; Xu, X.; Lei, P.; Liu, X.; Su, Y.; Dong, L.; Feng, J.; Zhang, H. Nd³⁺-sensitized NaLuF₄ luminescent nanoparticles for multimodal imaging and temperature sensing under 808 nm excitation. *Nanoscale* **2015**, *7*, 17861–17870. [[CrossRef](#)] [[PubMed](#)]
62. Yu, Z.; Fu, X.; Zheng, S.; Zhang, H. Nd³⁺ doped LuOF nanophosphors for bimodality imaging of NIR-to-NIR-II luminescence and X-Ray computed tomography. *J. Lumin.* **2021**, *231*, 117753. [[CrossRef](#)]
63. Gruber, J.B.; Burdick, G.W.; Woodward, N.T.; Dierolf, V.; Chandra, S.; Sardar, D.K. Crystal-field analysis and Zeeman splittings of energy levels of Nd³⁺ (4f³) in GaN. *J. Appl. Phys.* **2011**, *110*, 043109. [[CrossRef](#)]
64. Balda, R.; Fernández, J.; Mendioroz, A.; Adams, J.; Boulard, B. Temperature-dependent concentration quenching of Nd³⁺ fluorescence in fluoride glasses. *J. Phys. Condens. Matter* **1994**, *6*, 913. [[CrossRef](#)]
65. Galdino, F.E.; Picco, A.S.; Sforca, M.L.; Cardoso, M.B.; Loh, W. Effect of particle functionalization and solution properties on the adsorption of bovine serum albumin and lysozyme onto silica nanoparticles. *Colloids Surf. B Biointerfaces* **2020**, *186*, 110677. [[CrossRef](#)] [[PubMed](#)]

66. Karmali, P.P.; Simberg, D. Interactions of nanoparticles with plasma proteins: Implication on clearance and toxicity of drug delivery systems. *Expert Opin. Drug Deliv.* **2011**, *8*, 343–357. [[CrossRef](#)]
67. Jain, A.; Fournier, P.G.; Mendoza-Lavaniegos, V.; Sengar, P.; Guerra-Olvera, F.M.; Iñiguez, E.; Kretschmar, T.G.; Hirata, G.A.; Juárez, P. Functionalized rare earth-doped nanoparticles for breast cancer nanodiagnostic using fluorescence and CT imaging. *J. Nanobiotechnol.* **2018**, *16*, 26. [[CrossRef](#)]
68. Dobrovolskaia, M.A.; Aggarwal, P.; Hall, J.B.; McNeil, S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. *Mol. Pharm.* **2008**, *5*, 487–495. [[CrossRef](#)]
69. Aime, S.; Botta, M.; Terreno, E. Gd (III)-based contrast agents for MRI. *Adv. Inorg. Chem.* **2005**, *57*, 173–237.
70. Bourlinos, A.B.; Bakandritsos, A.; Kouloumpis, A.; Gournis, D.; Krysmann, M.; Giannelis, E.P.; Polakova, K.; Safarova, K.; Hola, K.; Zboril, R. Gd (III)-doped carbon dots as a dual fluorescent-MRI probe. *J. Mater. Chem.* **2012**, *22*, 23327–23330. [[CrossRef](#)]
71. Aime, S.; Calabi, L.; Cavallotti, C.; Gianolio, E.; Giovenzana, G.B.; Losi, P.; Maiocchi, A.; Palmisano, G.; Sisti, M. [Gd-AAZTA]-: A new structural entry for an improved generation of MRI contrast agents. *Inorg. Chem.* **2004**, *43*, 7588–7590. [[CrossRef](#)] [[PubMed](#)]
72. Poornaprakash, B.; Chalapathi, U.; Babu, S.; Park, S.-H. Structural, morphological, optical, and magnetic properties of Gd-doped and (Gd, Mn) co-doped ZnO nanoparticles. *Phys. E Low-Dimens. Syst. Nanostruct.* **2017**, *93*, 111–115. [[CrossRef](#)]
73. Visscher, M.; Pouw, J.J.; van Baarlen, J.; Klaase, J.M.; Ten Haken, B. Quantitative analysis of superparamagnetic contrast agent in sentinel lymph nodes using ex vivo vibrating sample magnetometry. *IEEE Trans. Biomed. Eng.* **2013**, *60*, 2594–2602. [[CrossRef](#)] [[PubMed](#)]
74. Sheng, Y.; Liao, L.-D.; Bandla, A.; Liu, Y.-H.; Yuan, J.; Thakor, N.; Tan, M.C. Enhanced near-infrared photoacoustic imaging of silica-coated rare-earth doped nanoparticles. *Mater. Sci. Eng. C* **2017**, *70*, 340–346. [[CrossRef](#)]
75. Sheng, Y.; Liao, L.-D.; Bandla, A.; Liu, Y.-H.; Thakor, N.; Tan, M.C. Size and shell effects on the photoacoustic and luminescence properties of dual modal rare-earth-doped nanoparticles for infrared photoacoustic imaging. *ACS Biomater. Sci. Eng.* **2016**, *2*, 809–817. [[CrossRef](#)]
76. Montaseri, H.; Kruger, C.A.; Abrahamse, H. Inorganic nanoparticles applied for active targeted photodynamic therapy of breast cancer. *Pharmaceutics* **2021**, *13*, 296. [[CrossRef](#)]
77. Sun, M.; Wang, T.; Li, L.; Li, X.; Zhai, Y.; Zhang, J.; Li, W. The application of inorganic nanoparticles in molecular targeted cancer therapy: EGFR targeting. *Front. Pharmacol.* **2021**, *12*, 702445. [[CrossRef](#)]
78. Chow, J.C. Application of Nanomaterials in Biomedical Imaging and Cancer Therapy. *Nanomaterials* **2022**, *12*, 726. [[CrossRef](#)]
79. Chan, M.-H.; Chang, Z.-X.; Huang, C.-Y.F.; Lee, L.J.; Liu, R.-S.; Hsiao, M. Integrated therapy platform of exosomal system: Hybrid inorganic/organic nanoparticles with exosomes for cancer treatment. *Nanoscale Horiz.* **2022**, *7*, 352–367. [[CrossRef](#)]